Core Viewpoint - China National Pharmaceutical Group (国药控股) experienced a decline on February 20, 2026, primarily due to short-term market sentiment, liquidity factors, and industry environment [1] Stock Performance - On February 20, the stock opened at HKD 20.60, down 4.1% from the previous closing price of HKD 21.48, with an intraday low of HKD 20.60. The closing price was HKD 20.98, reflecting a daily decline of 2.33% and a trading volume of approximately HKD 1.00 billion. The Hang Seng Index fell by 1.10%, with the pharmaceutical distribution sector declining by 5.13%, making China National Pharmaceutical Group one of the worst performers among Hang Seng Index constituents [2] Reasons for Stock Price Movement - Liquidity vacuum amplified selling pressure: The southbound trading (港股通) was closed on that day, preventing mainland funds from entering the market, leading to weak buying interest. A small amount of selling pressure caused a rapid decline in stock price, particularly evident in the pharmaceutical sector [3] - Industry policy and performance expectations were lackluster: No positive developments were observed in the pharmaceutical industry during the Spring Festival holiday, and concerns about policy adjustments, such as volume-based procurement, persisted. Additionally, the company's revenue for the first three quarters of 2025 decreased by 2.47%, although net profit slightly increased by 0.53%, leading to investor skepticism regarding short-term performance improvement [3] - Weight stocks dragged down and sector rotation occurred: Funds shifted from high-valuation sectors like pharmaceuticals and technology to defensive sectors such as energy and real estate, resulting in concentrated selling of China National Pharmaceutical Group as a pharmaceutical heavyweight. Concurrently, major tech stocks like Baidu and Alibaba also experienced significant declines, exacerbating market risk aversion [3] - External market transmission: Chinese concept stocks in the U.S. experienced widespread declines during the Spring Festival holiday, leading to a correction in the Hong Kong market. This was compounded by delayed expectations for U.S. Federal Reserve interest rate cuts and heightened geopolitical risks in the Middle East, putting pressure on global growth stock valuations [3] Capital and Technical Analysis - Capital flow: Southbound funds have been consistently reducing holdings, with a net reduction of 3.45 million shares on February 12 and a cumulative net reduction of 33.64 million shares over the past 20 trading days. However, Lazard Asset Management increased its holdings by 1.163 million shares on February 2, raising its stake to 11.06% [4] - Technical indicators: The stock price fell below the 20-day moving average (HKD 21.037), with the MACD histogram turning negative at -0.041 and the KDJ J-line dropping to 53.64, indicating weak short-term momentum [4] Future Development - Recent strategic actions include a partnership with Betta Pharmaceuticals (贝达药业) focused on supply chain optimization as of January 4, 2026. However, the medical device distribution business continues to be impacted by centralized procurement, and overall performance recovery will depend on subsequent policy and demand changes [5]

Group 1 - Cencora is merging its subsidiary MWI Animal Health with privately held Covetrus, valuing the deal at $3.5 billion [1] - The transaction aims to allow Cencora to focus more on its core business [1] - Upon completion of the deal, Cencora will receive $1.25 billion in cash, $800 million in preferred stock, and $1.45 billion in common stock, while retaining a 34.3% non-controlling interest in the merged company [1]

Core Viewpoint - Cardina Health reported Q2 FY2026 revenue of $65.627 billion and net profit of $4.67 billion, both showing year-on-year growth and exceeding market expectations [1][2]. Financial Report Analysis - For Q2 FY2026, Cardina Health achieved revenue of $65.627 billion, representing an 18.75% year-on-year increase; net profit reached $4.67 billion, up 16.75% year-on-year. The growth was primarily driven by the pharmaceutical distribution business, although the gross margin was 3.52% and net margin was 0.71%, reflecting the low-margin nature of the industry. The revenue surpassed market expectations of $64.9381 billion, with earnings per share at $2.63, exceeding the forecast of $2.37 [2]. Institutional Perspectives - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on the better-than-expected performance and industry outlook. Among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13. The internal database indicates a forecast of $2.63 for Q2 earnings per share, reflecting a year-on-year increase of 36.27% [3]. Recent Events - The Q2 performance was disclosed on February 5, 2026. TD Cowen raised the target price on February 11, coinciding with a 1.05% overall increase in the healthcare sales sector [4]. Recent Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 4.94%, with a high of $230.81 on February 6 and a low of $219.58 on February 10. The closing price on February 11 was $224.25, reflecting a single-day increase of 1.81% with a trading volume of 1.3133 million shares. On February 6, trading volume peaked at 2.2507 million shares, indicating active trading that later declined. The internal database shows a price change of -1.29% during this period, primarily influenced by post-earnings volatility [5].

Group 1 - The China Securities Central Enterprises Dividend Index (931233.CSI) includes 50 stocks of central enterprises with stable dividend levels and high dividend yields, achieving a 1-year dividend yield of 6.75% as of December 10, which is higher than the 10-year government bond yield of 4.88% [1] - The Hang Seng High Dividend Yield Index (HSMCHYI.HI) consists of high dividend stocks from mainland companies listed in Hong Kong, with a 1-year dividend yield of 6.21% as of December 10, surpassing the 10-year government bond yield of 4.34% [1] - The Non-Standard Poor's Hong Kong Stock Connect Low Volatility Dividend Index (SPAHLVHP.SPI) includes 50 high dividend low volatility stocks listed in Hong Kong, with the Hong Kong Stock Connect Low Volatility Dividend ETF (159118) being the ETF with the lowest comprehensive fee tracking this index [1] Group 2 - Shanghai Pharmaceuticals (601607) announced a dividend of HKD 0.13215 per share, with an ex-dividend date of December 29, 2025, and a payment date of February 6, 2026 [2] - Shanghai Pharmaceuticals is not a component of the China Securities Central Enterprises Dividend Index (931233.CSI), the Hang Seng High Dividend Yield Index (HSMCHYI.HI), or the Non-Standard Poor's Hong Kong Stock Connect Low Volatility Dividend Index (SPAHLVHP.SPI) [2]

Group 1 - The China Securities Central State-Owned Enterprises Dividend Index (931233.CSI) includes 50 stocks of central enterprises with stable dividend levels and high dividend yields, achieving a 1-year dividend yield of 6.75% as of December 10, which is higher than the 10-year government bond yield of 4.88% [1] - The Hang Seng China Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI) consists of high dividend stocks from mainland companies listed in Hong Kong, with a 1-year dividend yield of 6.21% as of December 10, surpassing the 10-year government bond yield of 4.34% [1] - The Non-Standard Poor Hong Kong Stock Connect Low Volatility Dividend Hong Kong Dollar Index (SPAHLVHP.SPI) includes 50 high dividend low volatility stocks listed in Hong Kong, with the Hong Kong Stock Connect Dividend Low Volatility ETF (159118) being the ETF with the lowest comprehensive fee tracking this index [1] Group 2 - Shanghai Pharmaceuticals announced a dividend of HKD 0.13215 per share, with an ex-dividend date of December 29, 2025, and a payment date of February 6, 2026 [2] - Shanghai Pharmaceuticals is not a component of the China Securities Central State-Owned Enterprises Dividend Index (931233.CSI), the Hang Seng China Mainland Enterprises High Dividend Yield Index (HSMCHYI.HI), or the Non-Standard Poor Hong Kong Stock Connect Low Volatility Dividend Hong Kong Dollar Index (SPAHLVHP.SPI) [2]

Group 1 - The China Securities Central Enterprises Dividend Index (931233.CSI) includes 50 stocks of centrally controlled enterprises with stable dividend levels and high dividend yields, achieving a one-year dividend yield of 6.71% as of December 9, which is higher than the 10-year government bond yield of 4.84% [1] - The Hang Seng High Dividend Yield Index (HSMCHYI.HI) consists of high dividend stocks from mainland companies listed in Hong Kong, with a one-year dividend yield of 6.19% as of December 9, surpassing the 10-year government bond yield of 4.31% [1] - The Non-Standard Poor's Hong Kong Stock Connect Low Volatility Dividend Index (SPAHLVHP.SPI) includes 50 high dividend low volatility stocks listed in Hong Kong, with the Hong Kong Stock Connect Low Volatility Dividend ETF (159118) being the ETF with the lowest comprehensive fee tracking this index [1] Group 2 - Shanghai Pharmaceuticals announced a dividend of HKD 0.13215 per share, with an ex-dividend date of December 30, 2025, and a payment date of February 6, 2026 [1]

Group 1 - China Railway announced a dividend of HKD 0.0899 per share, with an ex-dividend date of December 1, 2025, and a payment date of December 23, 2025 [1] - Shanghai Pharmaceuticals declared a dividend of CNY 0.1200 per share, with no specified ex-dividend or payment dates [1] - Jacobson Pharmaceutical announced a dividend of HKD 0.0425 per share, with an ex-dividend date of December 1, 2025, and a payment date of December 18, 2025 [1] - Laopuhuang Gold declared a dividend of HKD 10.52 per share, with an ex-dividend date of November 20, 2025, and a payment date of January 15, 2026 [1] Group 2 - The CSI Central State-Owned Enterprises Dividend Index includes 50 stocks with stable dividend levels and high yields, with a one-year dividend yield of 5.67% as of November 18, higher than the 10-year government bond yield of 3.86% [2] - The Hang Seng Mainland Enterprises High Dividend Yield Index has a one-year dividend yield of 5.34% as of November 18, also higher than the 10-year government bond yield of 3.52% [2] - The largest investment vehicle tracking the CSI Central State-Owned Enterprises Dividend Index is the Hong Kong Central State-Owned Enterprises Dividend ETF [2]

Core Viewpoint - China National Pharmaceutical Group (国药控股) shares rose over 3%, reaching a new high of 20.86 HKD this year, driven by positive market sentiment and analyst recommendations [1] Group 1: Stock Performance - The stock price increased by 3.49% to 20.78 HKD, with a trading volume of 111.2 million HKD [1] - Morgan Stanley's report indicated a 70% to 80% probability of the stock price rising within the next 30 days, with a target price set at 22.5 HKD [1] Group 2: Company Performance - Two subsidiaries of China National Pharmaceutical Group reported positive third-quarter results, indicating a positive trend for the group [1] - China National Pharmaceutical Co. (国药股份) saw a year-on-year revenue and profit increase of 4% and 13%, respectively, in the third quarter [1] - China National Accord Medicines Corporation (国药一致) reported a year-on-year revenue and net profit decline of 2% and 10%, but noted that its distribution business is stabilizing and returning to growth [1] Group 3: Market Context - The pharmaceutical distributor sector is expected to remain under market scrutiny until 2025 due to weak domestic demand and ongoing technology licensing activities in China [1] - The current valuation of China National Pharmaceutical Group, based on a projected P/E ratio of 6.5 times for 2026, suggests a favorable entry point for investors [1]

Core Viewpoint - Morgan Stanley believes that the stock price of China National Pharmaceutical Group (01099) will rise within the next 30 days, with a probability of 70% to 80%, and has given a "Buy" rating with a target price of HKD 22.5 [1] Group 1: Company Performance - Two subsidiaries of China National Pharmaceutical Group have reported third-quarter results showing a positive trend, which is expected to have a beneficial effect on the group [1] - China National Pharmaceutical Co., Ltd. (600511.SH), a major distributor in Beijing and a key supplier of anesthetic drugs, reported a year-on-year revenue and profit increase of 4% and 13% respectively in the third quarter, indicating a positive turnaround [1] - China National Pharmaceutical Group's southern distribution network and Guoda Pharmacy chain, represented by China National Pharmaceutical Holdings (000028.SZ), experienced a year-on-year revenue and net profit decline of 2% and 10% respectively in the third quarter, but the company noted that its distribution business has "stabilized and is recovering growth" [1] Group 2: Market Outlook - The pharmaceutical distributor is expected to remain under market attention until 2025 due to weak domestic demand and the impact of technology licensing activities in China [1] - Based on a projected price-to-earnings ratio of 6.5 times for 2026, Morgan Stanley considers that China National Pharmaceutical Group currently presents a good entry opportunity [1]

Financial Data and Key Metrics Changes - The company has increased its EPS guidance to a range of $15.85 to $16, reflecting strong performance in fiscal year 2025 [7] Business Line Data and Key Metrics Changes - The U.S. Healthcare Solutions segment has been a significant driver of growth, with broad-based strong performance across all U.S. businesses [6][9] - Specialty pharmaceuticals continue to be a key growth area, with strong sales to physician practices and health systems [9][10] Market Data and Key Metrics Changes - The international segment, which contributes 15% of operating income, has faced challenges, particularly in global specialty logistics and consulting businesses [63][64] - There is an expectation for improved performance in the international business in fiscal year 2026 due to a rebound in clinical trial activity [66] Company Strategy and Development Direction - The company focuses on three growth priorities: leading with market leaders, strengthening its position in specialty markets, and enhancing patient access to pharmaceuticals [3][4] - Four strategic drivers include digital transformation, prioritizing growth-oriented investments, productivity improvements, and talent and culture [5][6] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the market, citing strong fundamentals and utilization trends as key drivers of growth [12][13] - The company is cautious about potential changes in the insured population and their impact on pharmaceutical access [28][30] Other Important Information - The company is committed to investing approximately $600 million in CapEx, primarily in technology and infrastructure [74] - There is a focus on strategic M&A, particularly regarding OneOncology and Retina Consultants of America [74] Q&A Session Summary Question: What are the key drivers of the company's strong growth this year? - Management attributes growth to strong utilization trends, sales of specialty products, and broad-based performance across U.S. businesses [9] Question: How does the company view the sustainability of its growth? - Management acknowledges strong recent performance but emphasizes a prudent approach to long-term guidance, evaluating market conditions annually [12] Question: What is the impact of revenue versus profit growth in the U.S. business? - The company explains that profit growth is driven by product mix changes, with some lower-margin products being replaced by higher-margin alternatives [14][17] Question: How is the company planning for COVID vaccine demand? - Management discusses the importance of understanding customer booking expectations and the variability in demand based on approvals [24][26] Question: What are the expectations for the international business moving forward? - Management expresses optimism for growth in the international segment in fiscal year 2026, citing easier comparisons and a rebound in clinical trial activity [66] Question: How is the integration process for Retina Consultants of America progressing? - The integration is reported to be going well, with strong collaboration between teams and a focus on capital investment priorities [45] Question: What is the company's approach to capital deployment? - The company plans to balance investments in the business, strategic M&A, share repurchases, and dividend growth [72][75]